Markerless Motion Capture to Quantify Functional Performance in Neurodegeneration: Systematic Review.

Parkinson's disease body tracking clinical decision making decision decision making dementia markerless motion capture mild cognitive impairment mobility monitoring motion motion analysis movement movement analysis neurodegeneration neurodegenerative neurodegenerative disease systematic review tool tracking

Journal

JMIR aging
ISSN: 2561-7605
Titre abrégé: JMIR Aging
Pays: Canada
ID NLM: 101740387

Informations de publication

Date de publication:
06 Aug 2024
Historique:
received: 08 09 2023
accepted: 15 07 2024
revised: 22 03 2024
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 6 8 2024
Statut: epublish

Résumé

Markerless motion capture (MMC) uses video cameras or depth sensors for full body tracking and presents a promising approach for objectively and unobtrusively monitoring functional performance within community settings, to aid clinical decision-making in neurodegenerative diseases such as dementia. The primary objective of this systematic review was to investigate the application of MMC using full-body tracking, to quantify functional performance in people with dementia, mild cognitive impairment, and Parkinson disease. A systematic search of the Embase, MEDLINE, CINAHL, and Scopus databases was conducted between November 2022 and February 2023, which yielded a total of 1595 results. The inclusion criteria were MMC and full-body tracking. A total of 157 studies were included for full-text screening, out of which 26 eligible studies that met the selection criteria were included in the review. . Primarily, the selected studies focused on gait analysis (n=24), while other functional tasks, such as sit to stand (n=5) and stepping in place (n=1), were also explored. However, activities of daily living were not evaluated in any of the included studies. MMC models varied across the studies, encompassing depth cameras (n=18) versus standard video cameras (n=5) or mobile phone cameras (n=2) with postprocessing using deep learning models. However, only 6 studies conducted rigorous comparisons with established gold-standard motion capture models. Despite its potential as an effective tool for analyzing movement and posture in individuals with dementia, mild cognitive impairment, and Parkinson disease, further research is required to establish the clinical usefulness of MMC in quantifying mobility and functional performance in the real world.

Sections du résumé

BACKGROUND BACKGROUND
Markerless motion capture (MMC) uses video cameras or depth sensors for full body tracking and presents a promising approach for objectively and unobtrusively monitoring functional performance within community settings, to aid clinical decision-making in neurodegenerative diseases such as dementia.
OBJECTIVE OBJECTIVE
The primary objective of this systematic review was to investigate the application of MMC using full-body tracking, to quantify functional performance in people with dementia, mild cognitive impairment, and Parkinson disease.
METHODS METHODS
A systematic search of the Embase, MEDLINE, CINAHL, and Scopus databases was conducted between November 2022 and February 2023, which yielded a total of 1595 results. The inclusion criteria were MMC and full-body tracking. A total of 157 studies were included for full-text screening, out of which 26 eligible studies that met the selection criteria were included in the review. .
RESULTS RESULTS
Primarily, the selected studies focused on gait analysis (n=24), while other functional tasks, such as sit to stand (n=5) and stepping in place (n=1), were also explored. However, activities of daily living were not evaluated in any of the included studies. MMC models varied across the studies, encompassing depth cameras (n=18) versus standard video cameras (n=5) or mobile phone cameras (n=2) with postprocessing using deep learning models. However, only 6 studies conducted rigorous comparisons with established gold-standard motion capture models.
CONCLUSIONS CONCLUSIONS
Despite its potential as an effective tool for analyzing movement and posture in individuals with dementia, mild cognitive impairment, and Parkinson disease, further research is required to establish the clinical usefulness of MMC in quantifying mobility and functional performance in the real world.

Identifiants

pubmed: 39106477
pii: v7i1e52582
doi: 10.2196/52582
doi:

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e52582

Informations de copyright

©Julian Jeyasingh-Jacob, Mark Crook-Rumsey, Harshvi Shah, Theresita Joseph, Subati Abulikemu, Sarah Daniels, David J Sharp, Shlomi Haar. Originally published in JMIR Aging (https://aging.jmir.org), 06.08.2024.

Auteurs

Julian Jeyasingh-Jacob (J)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

Mark Crook-Rumsey (M)

Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.
Department of Basic and Clinical Neuroscience, King's College London, London, United Kingdom.

Harshvi Shah (H)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

Theresita Joseph (T)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

Subati Abulikemu (S)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

Sarah Daniels (S)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

David J Sharp (DJ)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

Shlomi Haar (S)

Department of Brain Sciences, Imperial College London, London, United Kingdom.
Care Research and Technology Centre, UK Dementia Research Institute, Imperial College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH